Realheart Receives Grant From Vinnova for Assembly Processes of Its Artificial Heart

As Realheart takes steps forward in the preclinical development of Realheart® TAH, the assembly process. Therefore, a project is now underway to develop a high-quality and scalable manufacturing method that will eventually enable a continuous production flow. The grant from Vinnova will finance a part-time consultancy position for a mechanical engineer with specialist expertise in process and production development of implantable medical devices. The person in this position has previous experience in leading and supporting this type of development project.

The grant is awarded in the framework of the ‘Strengthening Competence in Small Business 2024’ and ‘Collaborative Projects for Better Health’ programs funded by the Medtech4Health public innovation program. The program aims to enable the clinical implementation of medical technology ideas and solutions in consultation with healthcare, academia and industry.

‘As the company's preclinical projects progress, new development needs arise. To be able to meet the clinical demand for our artificial heart, Realheart® TAH, a high-quality, scalable and validated production capacity is required. We are therefore very grateful for the Vinnova grant, which makes it possible to bring in additional external expertise as we now establish assembly processes’, says Ina Laura Perkins, CEO of Realheart.

About Medtech4Health
Medtech4Health strive to increase the number and quality of new innovative products and services within MedTech. In collaboration with patients, healthcare, academia, and business, we contribute to increasing value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the Swedish innovation authority Vinnova, Swedish Energy Agency and Swedish Research Council for Sustainable Development Formas, and by the programme’s partners.
www.medtech4health.se

About Realheart
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow patterns of the human heart. These unique product characteristics provide new opportunities to save lives and provide patients with a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models for a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, please visit www.realheart.se